Evolving treatment landscape for early and advanced pancreatic cancer

Table 1 Summary of adjuvant studies for early stage pancreatic cancer

Adjuvant systemic therapy
Study[20,22-24,26,27,29]	Treatment	Treatment group				Control group
DFS (mo)	OS (mo)	2 yr survival	5 yr survival	DFS (mo)	OS (mo)	2 yr survival	5 yr survival
5-FU based treatments
ESPAC-1 Neoptolemos et al[20], 2001	5-FU/LV vs observation	-	19.7	-	-	-	14.0	-	-
ESPAC-1 and 3 pooled analysis Neoptolemos et al[22], 2009	5-FU/LV vs observation	-	23.2	49.0%	24.0%	-	16.8	37.0%	14.0%
Gemcitabine based treatments
CONKO-001, Oettle et al[24], 2007	Gemcitabine vs observation	13.4	22.1	-	16.5%	6.9	20.5	-	5.5%
JSAP-02, Ueno et al[26], 2009	Gemcitabine vs observation	11.4	22.3	48.3%	23.9%	5.0	18.4	40.0%	10.6%
Gemcitabine compared to 5-FU
ESPAC-3, Neoptolemos et al[23], 2010	Gemcitabine vs 5-FU/LV	14.3	23.6	29.6%	-	14.1	23.0	30.7%	-
RTOG 97-04, Regine et al[27], 2008	Gemcitabine vs 5-FU/LV in patients receiving CRT	-	20.5	-	-	-	16.9	-	-
Combination treatments
ESPAC-4, Neoptolemos et al[29], 2017	Gemcitabine plus capecitabine vs Gemcitabine	13.9	28.0	53.8%	-	13.1	25.5	52.1%	-

5-FU: 5-flurouracil; LV: Leucovorin; DFS: Disease free survival; OS: Overall survival.

Table 2 Summary of first line studies for advanced pancreatic cancer

First line treatment for metastatic disease
Study[41,49,63-67,71]	Treatment	Treatment group				Control group
ORR	PFS (mo)	OS (mo)	1 yr Survival	ORR	PFS (mo)	OS (mo)	1 yr Survival
Standard of care
Burris et al[41], 1997	Gemcitabine vs 5-FU/LV	-	9 wk	5.65	18.0%	-	4 wk	4.01	2.0%
Conroy et al[49], 2011	FOLFIRINOX vs Gemcitabine	31.6%	6.4	11.1	48.4%	9.4%	3.3	6.8	20.6%
Von Hoff et al[71], 2013	Nab-paclitaxel plus gemcitabine vs gemcitabine	23.0%	5.5	8.5	35.0%	7.0%	3.7	6.7	22.0%
Gemcitabine doublets
Berlin et al[63], 2002	Gemcitabine plus 5-FU vs gemcitabine	6.9%	3.4	6.7	-	5.6%	2.2	5.4	-
Herrmann et al[64], 2007	Gemcitabine plus capecitabine vs gemcitabine	10.0%	4.3	8.4	32.0%	7.8%	3.9	7.2	30.0%
Moore et al[66], 2007	Gemcitabine plus erlotinib vs gemcitabine	8.6%	3.8	6.2	23.0%	8.0%	3.6	5.9	17.0%
Philip et al[67], 2010	Gemcitabine plus cetuximab vs gemcitabine	12.0%	3.4	6.3	-	14.0%	3.0	5.9	-
Ueno et al[65], 2013	Gemcitabine plus S1 vs gemcitabine	29.3%	5.7	10.1	40.7%	13.3%	4.1	8.8	35.4%

5-FU: 5-flurouracil; LV: Leucovorin; DFS: Disease free survival; OS: Overall survival; ORR: Overall response rate.